Document:

EX-10.4

 Exhibit 10.4 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 
 Execution version 

ADDENDUM N°3 TO THE AGREEMENT 

Between: 
  

	 	•	 	ERYTECH Pharma, S.A. with a share capital of 792 461,10 euros €, having its registered head office in Lyon 08, Bâtiment Adénine, 60 avenue Rockefeller, registered with the Trade and Companies
Registry of Lyon under the number 479 560 013, represented by Mr Gil BEYEN, Chief Executive Officer, (“ERYTECH”) 

and 
  

	 	•	 	ORPHAN EUROPE, S.A.R.L., with share capital of 320,000 €, having its registered head office in Puteaux, Immeuble Le Wilson, 70 Avenue du Général de Gaulle, registered with the Trade and
Companies Registry of Nanterre under number 379 088 115, represented by Mr Andrea Recordati, Managing Director and Mr Massimo Mineo, General Manager EMEA (“OE”) 

PREAMBLE 
 On 22 November 2012
ERYTECH and OE signed a License and Distribution Agreement (hereinafter referred to as the “Agreement”), according to which, amongst others, ERYTECH appointed OE as its exclusive distributor of the Product for the Primary
Indications in the Territory and granted OE a license to the Licensed IP and the Trade Mark. 
 ERYTECH is finalizing with Medac GmbH some amendments to the
Medac Agreements, concerning the supply of the L-asparaginase (native or recombinant, as the case may be) for the Product and the related supply price, as well as the term of the Medac Agreements. The execution versions of the addenda, respectively,
to the 2008 Medac Agreement and to the 2011 Medac Agreement are attached hereto (the “Medac Addenda”). 
 In consideration of the above and
of the terms of the Medac Addenda, ERYTECH and OE wish to amend the Agreement in order to adjust their contractual relationship to the new terms of the Medac Agreements. 

IN CONSIDERATION OF THE MUTUAL COVENANTS EXPRESSED HEREIN, WHICH ARE INTEGRAL AND ESSENTIAL PART OF THIS ADDENDUM, THE PARTIES HERETO AGREE AS FOLLOWS:

 A) If not otherwise specified in this Addendum, capitalized terms shall have the meaning attributed to them in the Agreement. 

B) Subject to the terms hereof and to the execution of the Medac Addenda, pursuant to Art. 17.1 (O), OE [***]. 

Any proposal by ERYTECH to [***] shall be subject to a [***], unless [***] is required by Applicable Laws. It is understood that [***], having in mind its
interest in marketing the Product, and maximizing its margin from such marketing, under the Agreement. 
 It is also agreed that ERYTECH shall bear all
costs and expenses [***] (including, by way of example, costs and expenses for [***]). 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

Execution version 
 C) The Parties agree that the price for the
supply of a [***] of [***] of [***] (being an item of the “[***]” under paragraph (i) of the “Supply Price” calculation in Schedule 1.1.4. to the Agreement), in the form of [***] and delivered to ERYTECH according to the 2011
Medac Agreement (as amended and integrated from time to time), (the “Medac Product”) shall be charged by ERYTECH (as duly documented by ERYTECH) to OE at [***]. 

The Parties agree that [***] the price to be charged by ERYTECH to OE (as an item of the “[***]” under paragraph (i) of the “Supply Price”
calculation in Schedule 1.1.4. to the Agreement) shall [***]; therefore, [***] and [***] shall be [***] by [***]. 
 D) As a consequence of point C) above:

  

	 	(i)	[***] (being an item of “[***]” under such definition/calculation of “Supply Price” as per Schedule 1.1.4 to the Agreement) according to point C) above and to reflect the above described mechanism;
and 

  

	 	(ii)	Schedule 1.1.4 (Cost items in the Supply Price calculation) of the Agreement shall be cancelled and replaced with the new Schedule 1.1.4 attached to this Addendum; and 

 

	 	(iii)	[***] on the [***] shall be [***] according to the provisions of this Addendum. 

 E) Art. 17.5 and 17.6 of the
Agreement are hereby deleted and cancelled. 
 F) Schedule 1.1.3 (List of Patents in Licensed IP) of the Agreement is updated as per Schedule F to this
Addendum. 
 G) The definition of Territory is amended as follows: shall mean the 28 countries currently forming the European Union, Norway, Switzerland,
Liechtenstein, Iceland, Serbia, Macedonia, Montenegro, Kosovo, Albania, and Bosnia and Herzegovina, including their current possessions and territories. In case a country currently member of the European Union is no longer a member of the European
Union, it is understood that such country shall be in any case considered a country of the Territory. 
 H) This Addendum, including the related
attachments, is essential and integral part of the Agreement. Except as expressly set forth by this Addendum, all terms and conditions of the Agreement as amended shall remain unchanged and in full force and effect. 

In two originals, 
  

	
	 For ERYTECH
 On : 07 / 07 /
2016

	
	/s/ Gil Beyen
	Mr Gil BEYEN
	Chief Executive Officer

 For OE 
 On : 21 / 07 /
2016 
 Execution version 
  

	
	/s/ Andrea Recordati
	Mr Andrea Recordati
	Gérant/Managing Director
	
	/s/ Massimo Mineo
	Mr Massimo Mineo
	General Manager EMEA

 Execution version 

SCHEDULE B): Execution versions of the addenda to the Medac Agreements 

 

	A)	Execution version of Addendum 2 to the 2008 Medac Agreement 

 ADDENDUM N° 2 TO 

EXCLUSIVE SUPPLY AGREEMENT 

for L-Asparaginase 

This Addendum is entered between: 
 ERYTECH Pharma S.A, a
company incorporated under the laws of the Republic of France (n° 479 560 013 RCS Lyon; VAT No. FR 10479560013)), having its registered head office at Bâtiment Adenine, 60 avenue Rockefeller, 69008 Lyon, France, represented by Mr
GIl Beyen, Chief Executive Officer, and by Mr Jérôme Bailly, Qualified Person, 
 hereinafter referred to as “ERYTECH
Pharma”. 
 And, 
 medac GmbH, a
company having its registered head office at Theaterstrasse 6, D22880 Wedel, Germany represented by Mr Nikolaus Graf Stolberg, Managing Director and Dr. Michaela Rehberg, Director Drug Regulatory Affairs (VAT No. DE 118579535) 

hereinafter referred to as “Medac”. 

hereinafter referred to individually or collectively as the “Parties” and individually as a “Party”. 

WHEREAS 
 The Parties have signed an Exclusive Supply
Agreement on 12th December 2008, as amended by virtue of Addendum 1 executed on 19th August 2009, (hereinafter “the
Agreement”). 
 The Parties agree to modify certain Articles of the Agreement. 

Therefore, the Agreement is hereby amended to read as follows: 
  

	1)	The exclusivity of supply set forth in Section 3.1 of the Agreement shall be converted into non-exclusivity. 

 

	2)	Section 4.3 of the Agreement shall be null and void. 

  

	3)	Section 15.1 of the Agreement shall be null and void and replaced by the following: 

“15.1. Term. 

The term of this Agreement shall commence upon the Effective Date (i.e. 10th December
2008) and unless terminated earlier or extended pursuant to this Agreement shall expire twenty (20) years thereafter (i.e. 10th December 2028). 

It is agreed between the Parties that in the event that after December 31, 2017, Medac’s supplier of the Product discontinues
in full the production of the Product for supplies to medac for the EU countries, the Agreement is suspended, including all rights and obligations of the Parties. This means that neither Party may claim or be liable for any contractual rights and/or
obligations accordingly (with exception to Article XI. Confidentiality, Article XIII. Indemnification and Article XIV. Insurance). 

It is understood between the Parties that in case the circumstance under the proceeding sentence occurs, Medac will not be deemed liable
for the lack of supply of the Product to ERYTECH Pharma according to the Agreement and ERYTECH Pharma shall not be entitled to claim any compensation, direct, indirect, incidental or consequential losses or damages howsoever caused, and whether
based on warranty, contract, tort including negligence, strict liability or otherwise from Medac. 
  

	4)	Section 15.2 of the Agreement shall be amended as follows: 

 “15.2. b):

 [...]. Such possibility of termination does not exist in case of suspension of the Agreement according to Article 15.1.
second paragraph of the Agreement. 

  
 Page 4 of 3

 “15.2. c): 

After December 31, 2017, without notice and compensation by Medac in case (a) the European Commission definitely denies the
current marketing authorisation application for GRASPA® (EMEA/H/C/004055) (the “MAA”), (b) ERYtech withdraws the
MAA or (c) ERYtech changes the MAA from using the Product to recombinant L-Asparaginase and obtains the marketing authorization relating to the changed MAA. 

 

	5)	Section 15.3 first paragraph of the Agreement shall be null and void and replaced by the following: 

“15.3. Consequences of Termination 

Except with respect to a termination by Medac pursuant to Section 15.2. b), the expiration or termination of this Agreement will not
relieve Medac from its obligation to provide with any Product to be delivered prior to the effective date of such expiration or termination.” 
  

	6)	Except as otherwise provided herein, all terms and conditions of the Agreement shall remain in full force and effect and all terms beginning by a capitalized letter shall have the same meaning as those defined in the
Agreement. 

 IN WITNESS whereof, the Parties have caused this Addendum to be executed by their duly authorized officers. 

 

					
	 ERYTECH Pharma
  
	  	
	Mr Gil Beyen	  	Place and date:	  	
	Chief Executive Officer	  		  	
		  	Lyon, July 5th, 2016	  	
	/s/ Gil Beyen	  		  	
			
	Signature	  		  	
		
	 ERYTECH Pharma
  
	  	
	Mr Jérôme Bailly	  	Place and date:	  	
	Qualified Person	  		  	
		  	Lyon, July 5th, 2016	  	
	/s/ Jérôme Bailly	  		  	
			
	Signature	  		  	
		
	 Medac
  
	  	
	Mr Nikolaus Graf Stolberg	  	Place and date:	  	
	Managing Director	  		  	
		  	Hamburg, July 15th, 2016	  	
	/s/ Nikolaus Graf Stolberg	  		  	
			
	Signature	  		  	

  
 Page 5 of 3

					
		
	 Medac
  
	  	
	ppa. Dr. Michaela Rehberg	  	Place and date:	  	
	Director Drug Regulatory Affairs	  		  	
		  	Hamburg, July 25th, 2016	  	
	/s/ Dr. Michaela Rehberg	  		  	
			
	Signature	  		  	

  
 Page 6 of 3

	B)	Execution version of Addendum 2 to the 2011 Medac Agreement 

 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

ADDENDUM N° 2 TO 

EXCLUSIVE SUPPLY AGREEMENT 

for recombinant L-Asparaginase 
 This
Addendum is entered between: 
 ERYTECH Pharma S.A, a company incorporated under the laws of the Republic of France (n° 479 560 013 RCS Lyon; VAT
No. FR 10479560013)), having its registered head office at Bâtiment Adenine, 60 avenue Rockefeller, 69008 Lyon, France, represented by Mr Gil Beyen, Chief Executive Officer, and by Mr Jérôme Bailly, Qualified Person, 

hereinafter referred to as “ERYTECH Pharma”. 

And, 
 medac GmbH, a company having its
registered head office at Theaterstrasse 6, D22880 Wedel, Germany represented by Mr Nikolaus Graf Stolberg, Managing Director and Dr. Michaela Rehberg, Director Drug Regulatory Affairs (VAT No. DE 118579535) 

hereinafter referred to as “medac”. 

hereinafter referred to individually or collectively as the “Parties” and individually as a “Party”. 

WHEREAS 
 The Parties have signed an Exclusive Supply
Agreement on 3rd May 2011, as amended by virtue of Addendum 1 executed on 4th April 2014, (hereinafter “the
Agreement”). 
 The Parties agree to modify certain Articles of the Agreement. 

Therefore, the Agreement is hereby amended to read as follows: 
  

	1)	From the date of signature of this Addendum, for the avoidance of doubt, the term “GRASPA®”, which for purposes of the Agreement, designates the
medicinal product consisting in suspension of erythrocytes encapsulating recombinant L-asparaginase and released by ERYTECH Pharma, shall also include the medicinal product, internally designated as eryasp, consisting in suspension of erythrocytes
encapsulating recombinant L-asparaginase and released by ERYTECH Pharma, which may not be commercialized under the “GRASPA®” trademark. 

 

	2)	The exclusivity obligation under Section 3.1 of the Agreement (as well as any reference to such exclusivity obligation in the Agreement) shall be in force for five years from the first supply of the Product for
commercial purposes. 

  

	3)	Section 3.3 of the Agreement shall be null and void and replaced by the following: 

  

	 	3.3	Forecast 

  

	 	•	 	ERYTECH Pharma shall provide medac with a rolling forecast of the quantities to be purchased over the next [***] (“Forecast”) of which the first [***] shall be made of quarterly projections, while the
subsequent [***] shall be made of annual projections. 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

	4)	Sections 4.1.1 and 4.1.2. of the Agreement shall be null and void and replaced by the following: 

“4.1. Supply price of the Product 

The price of the Product will be according to the following table: 

 

			
	  

Order volumes
	  	  

Price per Product/ Euro

	 	 
	 [***] batch

 
	  	 [***]

 

	 	 
	 [***] batch

 
	  	 [***]

 

	 	 
	 [***] batches ([***] campaign per
year which will
 run from first Firm Order (“Commercial Year”)

 
	  	 [***]

 

	 	 
	 [***] batches ([***] campaigns of
[***] batches
 per Commercial Year)
  
	  	 [***]

 

	 	 
	 [***] batches ([***] campaigns of
[***] batches
 per Commercial Year)
  
	  	 [***]

 

 It is agreed that each batch comprises a number of Products between around [***] and around
[***].” 
  

	5)	Section V of the Agreement shall be null and void and replaced by the following: 

 Article V.
MUTUAL CONSENT 
 “[***].” 
  

	6)	Section 7.1 of the Agreement shall be null and void and replaced by the following: 

“7.1. Shipment. 

Except as set out in Article 3.6 hereof and as long as the purchase orders made by ERYTECH Pharma are in compliance with the Forecast as
defined under Article 3.3 hereof, medac shall ship, directly or through any Third Party, the Product to ERYTECH Pharma to one (1) delivery destination(s) in the European Union (in case of purchase order for commercial purposes) and any delivery
destinations in the European Union (in case of purchase order for clinical purposes) specified in ERYTECH Pharma`s purchase orders within the lead-times described below, each of which will run, following the Firm Order: 

(i) [***] for [***] batch, if [***] 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 (ii) [***] in case of [***] batch, if [***] 

(iii) [***] in case of [***] to [***] batches ([***] to [***] campaigns of [***] batches each) per [***], if [***] 

(iv) [***] in case of minimum [***] batches per Commercial Year, if [***] 

Pursuant to shipment of at least [***] batch, Medac shall deliver Products with [***] of the Product. 

[***]. 
  

	7)	Section 16.1 of the Agreement shall be cancelled and replaced with the following: 

“16.1. Term and termination 

The term of this Agreement shall commence upon the Effective Date and shall expire on
11th December 2028. 
 It is understood that save for the case of Force Majeure,
only following the expiration of the exclusivity period of five years as per Section 3.1 of this Agreement and only in the event that medac’s supplier of the API discontinues in full the production of the API and medac, therefore, becomes
unable to supply the Product to ERYTECH Pharma, medac will be entitled to terminate the Agreement, by sending ERYTECH Pharma a 5-years prior written notice. For the avoidance of doubt, during this 5-years notice period, medac shall remain committed
to ensure continuous supply of the Product in accordance with this Agreement.” 
  

	8)	Section 16.2 shall be cancelled and replaced with the following: 

 “16.2
Termination. The Agreement may be terminated: 
 a) without notice and compensation by the mutual written agreement of the
Parties; and 
 b) by either Party in the event a Party is in material default of the terms and conditions of this Agreement and fails to
remedy the material default within one hundred twenty (120) days after receiving written notice specifying such default.” 
  

	9)	Section XVIII below shall be added to the Agreement: 

 Article XVIII. RIGHT OF NEGOTIATION

 medac, on its behalf and on behalf of its Affiliates acknowledges, it has been informed and understood that: 

 

	 	•	 	as at the signature date of this Addendum, ERYTECH has granted to a partner with right to assign to [***] affiliates (hereinafter the “Partner”): 

 

	 	•	 	distribution and license rights with respect to a product developed by ERYTECH Pharma consisting of suspension of erythrocytes encapsulating L-Asparaginase: 

 

	 	•	 	in the 28 countries currently forming the European Union, [***]; and 

  

	 	•	 	for the ALL indication and the AML indication 

  

	 	•	 	a right of first negotiation notably in some additional territories, such as [***]. 

  

	 	•	 	In case of discrepancies between, the provisions of this Article 18 and any applicable provisions between the Partner and ERYTECH with respect to the rights granted as set out above, the provisions of this Article 18
will be modified automatically to the extent necessary to reflect what was agreed by the Partner and ERYTECH Pharma. ERYTECH Pharma shall notify medac of such modifications in writing. 

  

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 For the sole purpose of this Section, medac agrees and accepts that ERYTECH may disclose the existence of the
following sections to Third Parties. 
 18.1. Right of first negotiation 

In the event that within [***] of the date of this Addendum: 
  

	 	•	 	ERYTECH Pharma is no longer bound by the distribution and license rights granted to the Partner and 

  

	 	•	 	ERYTECH Pharma intends to enter into a license or other distribution arrangement with respect to GRASPA with any Third Party in relation to: 

 

	 	•	 	the 28 countries currently forming the European Union, [***] (hereinafter referred to as “Territories”); and in 

  

	 	•	 	the ALL indication and/or the AML indication (hereinafter referred to as “Indications”); 

 ERYTECH
Pharma shall notify medac of such intention in writing without undue delay. 
 18.2. Right of second negotiation 

In the event that within [***] of the date of this Addendum: 
  

	 	•	 	ERYTECH Pharma intends to enter into a license or other distribution arrangement with respect to GRASPA with any Third Party besides the Partner in relation to: 

 

	 	•	 	Turkey, Russia [***] (hereinafter referred to as “Additional Territories”); and to 

  

	 	•	 	the Indications, 

  

	 	•	 	and the Partner notifies ERYTECH Pharma that it does not wish to enter into discussions in relation to a license or other arrangement for such Additional Territories or Indications, or in the absence of any notification
by the Partner within a period mutually agreed by ERYTECH Pharma and the Partner, or if ERYTECH Pharma is no longer bound by the right of first negotiation with the Partner; 

ERYTECH Pharma shall notify medac of such intention in writing without undue delay. 

18.3. Negotiation’s proceedings 
 Within [***]
of ERYTECH Pharma’s notice to medac (within [***] if the notice falls in [***] or [***]), medac shall notify ERYTECH Pharma in writing whether it wishes to enter into discussions in relation to a license or other distribution arrangement with
ERYTECH Pharma for the Territories, Additional Territories and Indications for which medac has a right of first negotiation or second negotiation in accordance with Sections 18.1 and 18.2. If medac notifies ERYTECH Pharma that it does not wish to
enter into discussions in relation to a license or other distribution arrangement for such Territories, Additional Territories and Indications, or in the absence of any notification by medac within such period, ERYTECH Pharma shall be entitled to
enter into a license or other distribution arrangement in relation to such Territories, Additional Territories and Indications with a Third Party. 
 If
medac notifies ERYTECH Pharma that it wishes to enter into discussions in relation to a license or other distribution arrangement for such Territories, Additional Territories and indications the Parties shall negotiate exclusively in relation to the
same for a period of [***] from the response of medac. 
 If the Parties have not entered into a definitive agreement in relation to such Territories,
Additional Territories and Indications within the [***] period, ERYTECH Pharma shall be entitled to enter into a license or other distribution arrangement in relation to such Territories, Additional Territories and Indications with a Third Party
provided that the [***]. 

  

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 18.4 Right of information 

Without prejudice to the right of first negotiation of the Partner as described above, in the event that within [***] of the date of this Addendum: 

 

	 	•	 	ERYTECH intends to enter into a license or other distribution arrangement with respect to GRASPA with any Third Party in relation to: 

 

	 	•	 	countries where medac proves to be conducting significant distribution activities. Such countries are listed in Exhibit 4 and should be amended as the case may be by mutual agreement of the Parties; and to

  

	 	•	 	the Indications, 

 ERYTECH undertakes to inform medac of such intention in writing without undue delay. If
within [***] of ERYTECH Pharma’s notice to medac (within [***] if the notice falls in [***] or [***]), medac notifies ERYTECH Pharma that it wishes to make an offer in relation to a license or other distribution arrangement for such countries
and Indications, ERYTECH Pharma shall consider such offer in good faith but ERYTECH Pharma shall be free to enter into such license or other distribution arrangement with any Third Party. 

10) Section XIX below shall be added to the Agreement: 

“Article XIX: MUTUAL EFFORTS 
 medac
hereby authorises ERYTECH Pharma to use the information and documents related to the recombinant L-asparaginase, already provided to ERYTECH Pharma in connection with the GRASPA® registration
in ALL. 
 Without prejudice to the above, medac shall provide within a reasonable time and free of charge, ERYTECH Pharma with assistance and all the
information/documents related to the recombinant L-asparaginase available at medac and not being under confidentiality obligations towards third parties and necessary to obtain the marketing authorization of the product developed by ERYTECH Pharma
consisting of [***]. ERYTECH Pharma shall use reasonable commercial efforts to avoid any direct harm to medac. 
 If the documents/information to be
provided by medac according to the preceding sentence are under confidentiality obligations towards third parties, medac shall make reasonable efforts to obtain disclosure of said documents or information from such third parties. 

Without prejudice to the provisions of the Agreement as amended by this Addendum, ERYTECH Pharma shall [***].” 

11) In case medac wishes to carry out investment to improve the manufacturing capacity for the Product, the Parties shall promptly inform each other and send
the other Party a prospectus outlining the type of investment medac intends to make, and related costs and timeframes. Then, the Parties will discuss a possible cooperation and cost sharing, which shall not be unreasonably withheld by the Parties.

 12) Except as otherwise provided herein, all terms and conditions of the Agreement shall remain in full force and effect and all terms beginning by a
capitalized letter shall have the same meaning as those defined in the Agreement and in the Addendum n°1. 

  

 IN WITNESS whereof, the Parties have caused this Addendum to be executed by their duly authorized officers. 

ERYTECH Pharma 
  

					
	 Mr Gil Beyen
	  	Place and date:	  	
	 Chief Executive Officer
	  	Lyon, July 5th, 2016	  	
			
	 /s/ Gil Beyen
	  		  	
			
	 Signature
	  		  	
			
	 ERYTECH Pharma
  
	  		  	
	Mr Jérôme Bailly	  	Place and date:	  	
	Qualified Person	  	Lyon, July 5th, 2016	  	
			
	 /s/ Jérôme Bailly
	  		  	
			
	 Signature
	  		  	
			
	 Medac
  
	  		  	
	 Mr Nikolaus Graf Stolberg
	  	Place and date:	  	
	Managing Director	  	Hamburg, 15.7.16	  	
			
	 /s/ Nikolaus Graf Stolberg
	  		  	
			
	 Signature
	  		  	
			
	 Medac
  
	  		  	
	 ppa. Dr. Michaela Rehberg
	  	Place and date:	  	
	Director Drug Regulatory Affairs	  	Hamburg, 25.07.16	  	
			
	 /s/ Michaela Rehberg
	  		  	
			
	 Signature
	  		  	

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

Execution version 
 SCHEDULE F: Update of
SCHEDULE 1.1.3 of the Agreement (List of Patents in Licensed IP) 
 [***] 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

Execution version 
  

 SCHEDULE 1.1.4: Cost items in the Supply Price calculation 

[***]EX-10.5

 Exhibit 10.5 

***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 

EXCLUSIVE DISTRIBUTION AGREEMENT 
 This
Exclusive Distribution Agreement is made by and entered into as of 28/3/11 (the “Effective Date”) between: 
  

	•	 	ERYtech Pharma S.A, a Societé Anonyme existing and organized under the laws of the Republic of France, having its registered head office at 60 Avenue Rockefeller, Bâtiment Adenine, 69008 Lyon,
France, with a registered capital of 315.355 Euros; 

 Represented by Mr Pierre-Olivier Goineau, Chief Executive Officer, 

hereinafter referred to as “ERYTECH” 

OF THE FIRST PART, 
 AND: 

 

	•	 	Abic Marketing Limited, an Affiliate of TEVA Pharmaceutical Industries Limited, corporation existing and organized under the laws of Israel, having its registered head office at 5 Basel Street, Petah Tiqva,
49131, Israel 

 Represented by Ron Myron, Managing Director Teva Israel, Vice President I.C.A 

hereinafter referred to as “TEVA” 

OF THE SECOND PART, 
 ERYTECH and TEVA
hereinafter referred to individually a “Party” and collectively the “Parties”. 
 CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 Whereas TEVA and ERYTECH have signed on
June 24th, 2010 a term sheet in order to negotiate in good faith the terms and conditions of an exclusive distribution agreement. 

Whereas ERYTECH is a French specialty pharma company which develops personalized cell therapy medicinal products such as therapeutic molecules or
enzymes encapsulated into red blood cells. In particular, ERYtech Pharma develops the GRASPA® which consists of suspension of erythrocytes encapsulating L-asparaginase in a preservative
solution. ERYtech Pharma has started in Europe a Phase II/III clinical trial in relapse acute lymphoblastic leukemia in children and adults with GRASPA®, in view to grant a marketing
authorization. 
 Whereas TEVA is a global pharmaceutical company specializing in the development, production and marketing of generic and
proprietary branded pharmaceuticals as well as active pharmaceutical ingredients. 
 Whereas TEVA, is well established in Israel, and is already in
charge of importing, promoting, distributing and selling products for the chemical and pharmaceutical industry. 
 Whereas ERYTECH is willing to
entrust TEVA with the task of registering GRASPA® and with the task of importing, promoting, marketing and selling GRASPA® in Israel.

 IN CONSIDERATION of the mutual covenants herein contained and other good and valuable consideration the receipt and sufficiency of which are
hereby acknowledged, 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 IT IS AGREED BY AND BETWEEN THE PARTIES HERETO AS FOLLOWS: 

ARTICLE 1 - DEFINITIONS. 
  

	1.1	Where used herein the following terms shall have the following meanings respectively: 

  

	 	1.1.a	“Affiliates” means, with respect to any Party, (i) any legal entity of which the securities or other ownership interests representing fifty per cent (50 %) or more of the equity or fifty per cent
(50 %) or more of the ordinary voting power or fifty per cent (50 %) or more of the general partnership interest are, at the time such determination is being made, owned, Controlled or held, directly or indirectly, by such legal entity, or
(ii) any legal entity which, at the time such determination is being made, is Controlling or under common Control with, such legal entity. As used herein, the term “Control”, whether used as a noun or verb, refers to the possession,
directly or indirectly, of the power to direct, or cause the direction of, the management or policies of a legal entity, whether through the ownership of voting securities, by contract or otherwise. 

 

	 	1.1.b	“Agreement” means this Exclusive Distribution Agreement, all amendments to this Agreement, and all exhibits and schedules to this Agreement. 

 

	 	1.1.c	“Customer” means the Israeli hospital requesting the manufacture of a Product. 

  

	 	1.1.d	“Date of Launch” means the date on which TEVA has received the Product Approval for the Product in the Territory in the Primary Indication (as defined below). 

 

	 	1.1.e	“Date of Registration” means the date on which ERYTECH has received the commercial market authorization in a state of the European Union which is recognized as being able to serve as the reference for a
regulatory application by mutual recognition process in the Territory. 

  

	 	1.1.f	“Regulatory activities” means all regulatory activities (such as filing, pricing, reimbursement, inspection by Regulatory Authorities) in order to obtain and to maintain Product Approval(s) for the
Product in the Territory. 

  

	 	1.1.g	“Distribution” means all distribution activities (such as importation, promotion, marketing) in order to sell Products in the Territory in the Field. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	 	1.1.h	“Effective Date” means the date set out above. 

  

	 	1.1.i	“ERYTECH Background Rights” means any and all intellectual property rights that are (a) owned or controlled by ERYTECH prior to the Effective Date, or (b) owned or controlled by ERYTECH after
the Effective Date and developed in the performance of this Agreement and without use of TEVA’s proprietary technology, materials or know-how. 

  

	 	•	 	ERYTECH Background Rights includes (without limitation): 

 (a) ERYTECH Trademarks (as defined
below); 
 (b) French patent n° FR0408667 and any PCT extensions n° PCT/I B2005/002323; 

(c) Know-How related to entrapment and its optimization. 
  

	 	1.1.j	“ERYTECH Trademarks” means ERYtech Pharma®, GRASPA® and any other trade marks or
intellectual property rights related to the name of ERYTECH or its products, applied for registration, now owned or hereafter created or acquired by ERYTECH, used by ERYTECH as a licensee with authorization to sublicense, whether registered or not,
which TEVA is authorized to use in connection with the Agreement. 

  

	 	1.1.k	“Field” means the treatment of Acute Lymphoblastic Leukemia (the “Primary Indication”) and any other indications ERYTECH may develop for the Product (the “Additional
Indication”). 

  

	 	1.1.l	“Product” means a batch of suspension of erythrocytes encapsulating L-Asparaginase manufactured for a named patient, in a sufficient amount for one time administration as agreed with the Customer,
packed and labeled according to the Dossier and to Product Approval in the Territory. 

  

	 	1.1.m	“Product Approvals” shall mean all required consents, licenses, authorizations, export and/or import authorizations, update, changes and approvals that Regulatory Authorities having jurisdiction are
requested to issue in order to allow sales of Product in the Territory in the Field. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	 	1.1.n	“Dossier” shall mean all documents and information required by the Regulatory Authorities to grant Product Approval in the Territory. 

 

	 	1.1.o	“Regulatory Authority” means any federal, state or local regulatory agency, department, bureau or other governmental entity, that is responsible for issuing any Product Approvals in a regulatory
jurisdiction. 

  

	 	1.1.p	“Representatives” means, with respect to a Party to this Agreement, the respective officers, directors, employees, and/or agents of such Party and of such Party’s Affiliates. 

 

	 	1.1.q	“[***]” means [***]. 

  

	 	1.1.r	“Specifications” means all ERYTECH’s manufacturing and operating procedures and specifications for manufacturing and testing the Products, (as registered in the European Union which is recognized
as being able to serve as the reference for a regulatory application by mutual recognition process in the Territory), including without limitation labeling and packaging specifications. 

 

	 	1.1.s	“Territory” means Israel including Gaza strip and the West Bank, as it is internationally known as of the Effective Date. 

 

	 	1.1.t	“Third Party” means any person, company or legal entity other than a Party and such Party’s Representatives and Affiliates. 

 

	1.2	The following schedules are attached hereto and form part hereof: 

  

	 	•	 	Schedule A — Upfront and Milestones 

  

	 	•	 	Schedule B — Press Release 

  

	 	•	 	Schedule C — Traceability 

  

	 	•	 	Schedule D — Forecasts and GRASPA® Business Model 

  

	1.3	Unless otherwise indicated, Euro amounts (if any) expressed herein refers to lawful currency of the European Union. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 ARTICLE 2 APPOINTMENT AND EXCLUSIVITY 

 

	2.1	Appointment: Upon the terms and subject to the conditions herein set forth, ERYTECH hereby entrusts TEVA with the performance of the Regulatory activities so as to obtain, as soon as reasonably practicable
from the Date of Registration, Product Approval (s) in the Territory for the Distribution of the Product in the Field, under one or more ERYTECH Trademarks. 

ERYTECH appoints TEVA as its sole and exclusive distributor for the importation, promotion, marketing and sale of the Products, in the
Territory and TEVA hereby appoints ERYTECH as its exclusive supplier for the Products, in the Territory. 
  

	2.2	Exclusivity: 

 For the duration of this Agreement, the exclusivity prevents: 

ERYTECH: 
  

	 	•	 	from entrusting the Regulatory activities in the Territory with an entity other than TEVA and, 

  

	 	•	 	from selling the Product in the Territory to a distributor other than TEVA; 

 TEVA: 

 

	 	•	 	From performing the Regulatory activities of a Similar Product in the Territory and; 

  

	 	•	 	from producing, importing, promoting, marketing, selling and buying any Similar Products in the Territory. 

  

	2.3	Compassionate use of the Product 

 IF ERYTECH obtains the authorization to sell
the Product in Europe for compassionate use, the Parties shall discuss in the Steering Committee the possibilities and opportunities arising out of such authorization and decide together whether to utilize it in the Territory and the mutual
obligations arising thereof. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 ARTICLE 3 - OBLIGATIONS OF TEVA 

 

	3.1	TEVA covenants and agrees with ERYTECH that TEVA has the requisite experience, knowledge and expertise, qualified personnel and the legal right to perform the Agreement in a sound, safe, lawful and workmanlike manner,
in accordance with all laws, ordinances, orders, rules, regulations of the Territory. 

  

	3.2	Field: For avoidance of any doubt, TEVA acknowledges and agrees that its obligations (as set out in this Article 3) are binding in the Primary Indication. In any Additional Indications in which ERYTECH has
received the marketing authorization in the European Union, TEVA shall have the right not to register or distribute the Product in the Territory in such Additional Indication, In such a case and if the Steering Committee did not agree to postpone
the registration of the Additional Indication, and only with regard to the Additional Indications, ERYTECH will be released from its exclusivity obligations and shall be entitled: 

 

	 	•	 	To perform directly the Regulatory Activities in the Territory or to entrust the Regulatory activities in the Territory with an entity other than TEVA and; 

 

	 	•	 	To sell the Product in the Territory to a distributor other than TEVA or sell it directly. 

 For
avoidance of any doubt, in such a case, TEVA and ERYTECH shall not be released from any of their obligations of the Agreement for the Primary Indication and any other Additional Indication (exclusivity included). 

The Steering Committee shall take the final decision no later than one month after the meeting. 

 

	3.3	Regulatory activities 

  

	 	3.3.a	At least six (6) months before the provisional date of submission of the Dossier for a Product Approval, TEVA shall advise ERYTECH of all requirements, significant laws and regulations applicable in the Territory
relating to the Product with regards to (without any limitations): 

  

	 	•	 	the required content of the Dossier, 

  

	 	•	 	the safety reporting; 

  

	 	•	 	their manufacture, packaging, labeling, advertising, distribution and sale of the Product. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 ERYTECH shall provide TEVA with a provisional date in which it shall supply the Dossier,
including the dossier filed for the European Union, except if related to manufacturing process of the Product as planned in Article 5.5. 
  

	 	3.3.b	TEVA’s Regulatory Efforts. As soon as ERYTECH has provided TEVA with the Dossier (as set up in Article 5.5) TEVA agrees to use its best efforts to obtain and to maintain Product Approval in the Territory and
in the Field. From the same date, TEVA shall be responsible for all the Regulatory activities and shall bear all costs and expenses incurred in connection with such Regulatory activities and with Product Approval (“Regulatory
expenses”). 

 Updates and changes of Product Approvals shall be filed in the same way as the initial Product
Approvals and shall be agreed by TEVA and ERYTECH. 
  

	 	3.3.c	Any Product Approval shall be in the name of ERYTECH, or of an ERYTECH’s Affiliate appointed by ERYTECH, and while dealing in such matters, TEVA shall always act as agent, on behalf and in the name of ERYTECH or of
such ERYTECH’s Affiliate, using exclusively technical documentation provided by ERYTECH. 

  

	 	3.3.d	If a Product Approval must be in the name of TEVA for regulatory reasons, TEVA shall so inform ERYTECH and ERYTECH shall authorize TEVA to apply for the Product Approval in its own name but on behalf of ERYTECH, which
shall be deemed the beneficial owner of such Product Approval. At the termination of this Agreement for any reason whatsoever TEVA shall transfer to ERYTECH all Product Approvals free of charge. 

 

	 	3.3.e	TEVA shall provide ERYTECH with copies of registration certificates and other significant official documents relating to the Products and Product Approvals as soon as reasonably possible. 

 

	 	3.3.f	TEVA shall bear all expenses related to any update of any Product Approvals in case of new laws and new regulations applicable in the Territory relating to the Product with regards to their registration, advertising,
distribution and sale of the Products, provided that such expense is commercially reasonable. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	 	3.3.g	TEVA shall, at its own expenses, make any submissions and filing to each Regulatory Authority and all other Third Parties necessary or desirable to establish the Regulatory Price (as defined in Article 9 (Transfer Price
and Payments)) for use in the Field, in the Territory. 

  

	 	3.3.h	Reporting: Whenever TEVA receives any communication from any Regulatory Authority in connection with Products, concerning their medical profile, safety, efficacy or regulatory status TEVA shall forthwith forward to
ERYTECH a copy of such communication, along with a translation in English, or a report thereon, in writing and in English, if the communication was not made itself in writing. 

 

	 	3.3.i	Physical complaints: Each physical complaint will be notified to ERYTECH by TEVA with the defective sample, lot number, quantity, description of the defect within [***] from the detection of such a defect. For the
purpose of this Article, physical complaint shall mean any written electronic or oral communication that alleges deficiencies related to the appearance, labeling, identity, quality, safety, stability and efficacy of the product. 

 

	 	3.3.j	Specific recommendations: TEVA shall not change any part of the ERYTECH Product (carton, box, leaflet and label), except if such change is required by the Regulatory Authorities in the Territory and with the prior
consultation of ERYTECH. 

  

	 	3.3.k	General Standard Operating Procedure: TEVA undertakes to comply with the requirements and operating procedures given in the Product Approval in the Territory. 

 

	 	3.3.l	Destruction Standard Operating Procedure: Without prejudice to the foregoing, TEVA shall not return any Products to ERYTECH, nor it shall destroy any such Products, for any reason whatsoever, without the prior written
consent of ERYTECH which shall not be unreasonably withheld. If any ERYTECH Product has to be destroyed, the destruction will be performed according to an adapted and validated method. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	3.4	Distribution: 

  

	 	3.4.a	TEVA’s Efforts. 

  

	 	•	 	As an inducement to ERYTECH to enter into this Agreement, TEVA agrees, from the Date of Launch to use its best efforts to promote market and sell the Products in the Territory spending annually at least the amounts
agreed in the Schedule D (Forecasts and GRASPA® Business Model) to attain optimal sales level. TEVA shall bear all costs and expenses incurred in connection with such efforts.

  

	 	•	 	TEVA shall not detract from and disturb the good name of ERYTECH or the reputation of Products. 

  

	 	3.4.b	Non-competition obligation. 

 Unless authorized in advance in writing by ERYTECH, TEVA
shall not represent, manufacture, sell, market, promote, advertise or distribute (directly or indirectly): 
  

	 	•	 	in the Territory any products which are Similar Products, for the entire term of this Agreement; 

  

	 	•	 	the Product outside the Territory nor knowingly sell the Products, to any Third Party, in the Territory for resale outside the Territory, for the entire term of this Agreement. 

 

	 	3.4.c	Traceability. 

 TEVA shall comply with all traceability programs of ERYTECH agreed in
Schedule C (Traceability) in accordance with local regulatory requirements, which shall be updated from time to time and shall become effective only upon receipt of TEVA’s prior written approval. 

 

	 	3.4.d	Marketing and promotional campaign and material 

  

	 	•	 	 At the beginning of each calendar year from the Date of Launch, TEVA shall provide ERYTECH with a marketing plan
in English which shall be adequate to 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	 	 
attain optimal sales agreed in the Schedule D (Forecasts and GRASPA® Business Model), including marketing and promotional campaign for the
Product in the Territory. TEVA shall discuss the nature and extent thereof with ERYTECH. 

  

	 	•	 	TEVA shall transfer to ERYTECH a copy of any major new marketing and promotional document used to promote Products. In case these documents are not in the English language, the Steering Committee will decide which
documents TEVA shall translate. TEVA shall follow ERYTECH’s promotional strategy and shall make the needed adjustments for the Territory in accordance with local regulatory requirements. 

TEVA shall indemnify and save ERYTECH harmless from and against any and all costs and damages arising from the use of any marketing and
promotional materials not based on information received by ERYTECH and/or not conformed to local laws and to Product Approval. ERYTECH shall indemnify and save TEVA harmless from and against any and all costs and damages arising from the use of or
reliance on any marketing and promotional materials provided by ERYTECH. 
  

	 	•	 	TEVA shall be responsible for training all of its personnel who promote Products so that they are knowledgeable about the Products and can adequately represent the Products. ERYTECH shall provide all training materials
and cooperate in effecting such training. 

  

	 	•	 	ERYTECH shall provide TEVA with all documentation (such as the Summary of Product Characteristics and the labeling) in English related to the use of the Products. 

 

	 	•	 	TEVA shall be responsible for providing Customers with the above-mentioned documentation translated in Hebrew, if needed, and for training Customers so that they are knowledgeable about the use of the Products.

  

	 	•	 	 Marketing and promotional material and campaign shall be at TEVA’s cost and expense (“Marketing and
Promotional Expenses”). At the beginning of each calendar year, TEVA shall provide ERYTECH with a written report summarizing 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	 	 
the marketing and promotional expenses paid by TEVA during the preceding year for the marketing of the Product in the Territory. This report shall be certified by an internal accountant from
TEVA. 

  

	 	3.4.e	Forecasts 

 The “Forecast” shall include a non binding estimate of the
current trends identified for the Product, TEVA’s best estimate of the Product’s market share in the Territory, market average selling price for the Product currently re-sold by TEVA pursuant hereto, data on competition and general
business environment and trading conditions. The preliminary Forecast is agreed and attached hereto as Schedule D (Forecasts and GRASPA® Business Model). Once a year if necessary, and no later
than October 30, TEVA shall provide ERYTECH with an update of the Forecast, in writing and in English. 
  

	 	3.4.f	Sales Reporting: 

 Each quarter, TEVA shall provide detailed sales-reports indicating
detailed sales volumes for each Customer and total sales in value. This report shall be certified by an internal accountant form TEVA. 
  

	 	3.4.g	Audit 

 Not more than once a year, an independent auditor designated by ERYTECH shall
have the right, upon prior coordination with TEVA and during normal business hours, during the Term of this Agreement and for [***] following the expiration, termination or cancellation hereof, to audit and inspect, the TEVA’s books, records
and other materials with respect to Marketing and Promotional Expenses and to sales reporting, all if related directly to the Product. If any audit or inspection reveals an error or irregularity in the calculation of the transfer price payable to
ERYTECH hereunder, an appropriate adjustment shall be made promptly by the Parties. ERYTECH shall pay for any audit or inspection; unless such audit discloses an over payment to TEVA or other financial discrepancy of more than [***] in favor of TEVA
from the amount of total payments due for the period audited. In such case, TEVA will bear the full cost of such audit. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	 	3.4.h	Prohibition of active sales outside the Territory 

  

	 	•	 	TEVA acknowledges that ERYTECH may grant exclusive marketing rights to other persons to distribute the Products outside the Territory, or may retain exclusive marketing rights for itself and its Affiliates for the same
purpose. 

  

	 	•	 	TEVA covenants and agrees with ERYTECH that TEVA will not actively promote (e.g. through advertising, or by establishing branches or distribution depots) the Products, outside the Territory. 

ARTICLE 4 - ADVERSE EVENTS REPORTING 
  

	4.1	Pursuant to current regulations related to pharmacovigilance of drug products, and during the term of this Agreement, each Party shall notify the other within delays, stated by EMA regulations and the Israeli
Ministry of Health regulations, the stricter of the two, of any information (all in English) concerning any serious or unexpected adverse event, medication error, injury, toxicity or any unexpected incidence and the severity and seriousness thereof
associated with the use of the Products, whether or not determined to be attributable to the Products. 

  

	4.2	ERYTECH shall provide TEVA with necessary information on safety and efficacy profile of the Product including periodic safety report, investigator brochure, line listing, after receipt of the local requirements
for the submission of the Dossier (as set in Article 3.3.a) for Product Approvals and follow up of pharmacovigilance. 

  

	4.3	At time of exchanging information for the Dossier and before its submission, the Parties shall agree on procedures to follow to exchange safety data in accordance with the regulatory requirements. 

ARTICLE 5 - OBLIGATIONS OF ERYTECH 
  

	5.1	ERYTECH hereby represents that it has the requisite experience, knowledge and expertise, suitable facilities and qualified personnel and the legal right to perform the Agreement in a sound, safe, lawful and workmanlike
manner, in accordance with all laws, ordinances, orders, rules and regulations of France. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	5.2	Product Production: ERYTECH hereby covenant that the Product will be produced, packed and labeled according to the Product’s Dossier, cGMP requirements and the all relevant laws and regulation in the EMA and
the Territory, including without limitation, the Israeli Health Authority regulation for blood donations and the tests required of such blood donations, if such are required in the Territory. ERYTECH shall be responsible to manufacture the Product
in its facilities, as registered in the Product Approval in the Territory. 

  

	5.3	Changes: All changes in Specifications shall be communicated by ERYTECH to TEVA, prior to implementation. The Parties will review these changes, if needed, to be conformed to regulatory commitments. ERYTECH shall
supply Products that comply at all times with the Product Approvals in the Territory. 

  

	5.4	Sale and supply: ERYTECH agrees to sell Products to TEVA, which have been ordered by TEVA in accordance with this Agreement, and to supply TEVA regularly and promptly with the Products with information attached
as follows: 

  

	 	•	 	patient’s name, blood type, date of birth and weight; 

  

	 	•	 	Customer’s name and address; 

  

	 	•	 	date of production of the Product and its expiration date; and 

  

	 	•	 	the TEVA logo (in addition to ERYTECH’s logo) marked on the Product’s packaging. 

 all
in a form agreed upon by the parties on a later date and in accordance with ordering and delivery procedures set forth in Article 6 (Orders) and 9 (Transfer Price and Payment) hereof and in accordance with the regulatory specifications in the
Product Approval. 
  

	5.5	Assistance: ERYTECH agrees to reasonably assist TEVA as TEVA may require for the registration, maintenance and renewal of Product Approval(s). ERYTECH shall 

 

	 	•	 	either provide TEVA with any documents necessary for the Product Approval(s) (including without limitations, Certificate of Pharmaceutical Product); 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	 	•	 	Or provide directly the Regulatory Authorities with information necessary for the Product Approval(s) if the above-mentioned documents contained information related to manufacturing process of the Product (including
without limitations, Certificate of Pharmaceutical Product). 

  

	5.6	Transportation: ERYTECH shall be responsible for the transportation of the Product from its facilities to the Customer mentioned in the Order. The Product shall reach the above mentioned Customer at the date
agreed by the Parties and mentioned in the Firm Order, but in any case, within [***] of the manufacture of the Product and ERYTECH shall send TEVA a written confirmation of receipt (by e-mail) of the Product by the Customer. 

 

	 	5.6.a	ERYTECH shall pay all costs relating to the transportation of the Product from ERYTECH facility to the Customer (including all taxes, duties, charges or other expenses related the transportation of the Product)
(“The Transportation Costs”). 

 However, ERYTECH shall be reimbursed by TEVA: 

 

	 	•	 	for [***]% of all the Transportation Costs; and 

  

	 	•	 	for any amount exceeding [***] Euros (all taxes included) per Product. 

  

	 	5.6.b	The transportation shall be performed by a company agreed upon by both Parties and in accordance with all shipping instructions specified in any Product Approval(s) and with the ERYTECH’s requirements. ERYTECH
shall make sure that upon receipt of the Product by the Customer, the Product shall have a remaining shelf life of at least [***], shall comply with its Specifications and shall be ready for use. 

 

	5.7	Reporting: Whenever ERYTECH receives any significant communication from any Regulatory Authority in connection with Products, concerning their medical profile, safety, efficacy or regulatory status ERYTECH shall
forthwith forward to TEVA a copy of such communication, along with a translation in English, or a report thereon, in writing and in English, if the communication was not made itself in writing. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	5.8	Marketing and Medical Support: 

 ERYTECH shall provide TEVA with all significant
publications, campaigns and marketing materials, clinical data, and press releases relevant to the Product. ERYTECH shall inform TEVA as to the Product’s international clinical and marketing activities, such as clinical trials and conferences
relating the Product and/or Field. 
 In addition, ERYTECH shall provide TEVA with Products up to [***] per year for the longer of the two
following periods from the Effective Date: 
  

	 	•	 	[***] after the first Date of Registration, 

  

	 	•	 	[***] after the Date of Launch, 

 for which TEVA shall pay [***], in an amount of [***] per
Product. 
 Notwithstanding the above-mentioned, in any case, ERYTECH shall not provide TEVA with more than [***] Products in the aggregate
at [***]. 
 ARTICLE 6 - ORDERS 
  

	6.1	Firm Orders: TEVA shall send an order to ERYTECH, which shall include: 

  

	 	•	 	the delivery date , and 

  

	 	•	 	a valid prescription form signed by a clinician of the Customer. The template of the prescription form shall be communicated by ERYTECH as provided in Schedule C. The prescription form shall contain all
information requested [***]. 

 Promptly after receipt of TEVA’s order, ERYTECH shall inform TEVA of the acceptance of
such order. After such acceptance, the Parties shall consider the order as binding upon the Parties (“Firm Order”). 

ARTICLE 7 - SALES OBJECTIVES 

The Parties agree that minimum sales objectives are 
  

	 	•	 	[***] Products the second year following the Date of Launch; 

  

	 	•	 	[***] Products per year, commencing from the third year following the Date of Launch. 

Non-achievement of such minimum sales’ objectives, will allow ERYTECH to approach the Steering Committee in order to find a suitable
solution. In the event that such non-achievement of the minimum sales objectives is not reached for [***] in a period of 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 
[***], then ERYTECH shall have the right, within [***] days from the end of the [***] in which Teva did not achieve the minimum sales objective, to [***] in order to [***] and if such is not
found by [***], ERYTECH shall have the right to terminate this Agreement by [***], in which event [***]. 
 In the event that the Agreement
is not [***], and TEVA [***], ERYTECH shall have the right [***] to [***] in order to [***] and if such is not found, to provide TEVA with [***]. 

ERYTECH shall not pay TEVA any indemnity or reimbursements whatsoever for terminating this Agreement in accordance with this Article 7. 

For the avoidance of any doubt: 
  

	 	•	 	[***] shall not be included in the minimum sales objectives, 

  

	 	•	 	TEVA shall not be responsible or liable for any non-achievement of such minimum sales’ objectives if such non-achievement results from events or circumstances reasonably beyond the control of TEVA (or any of its
Representatives) and which, despite the exercise of reasonable diligence, TEVA is unable to prevent, avoid or remove. 

ARTICLE 8 - UPFRONTS AND MILESTONES 

In consideration of the Product development already made by ERYTECH at the Effective Date, TEVA shall pay to ERYTECH the upfront and milestones
payments as specified in Schedule A (Upfront and Milestones), by letter of credit issued by a bank of the Territory and confirmed by a first class bank in favor of ERYTECH, within [***] days after the last day of the month in which the
invoice was issued. Upfronts and Milestones shall be paid in Euros. 
 ARTICLE 9 - TRANSFER PRICE AND PAYMENT 

 

	9.1	Transfer Price. 

 TEVA shall purchase the Products with the conditions of the
[***] (Address of the Customer) in accordance with conditions of the INCOTERM issued by the International 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 
Chamber of Commerce, 2000. The price of a Product (the “Transfer Price”) shall be calculated as following: 

The Transfer Price shall be equaled to [***]% of the Total Sales. 

Total Sales = [***]. 

Regulatory Price = price of a Product in the Territory as it will be approved by the Israeli Regulatory Authorities, based on the
approved price in the reference countries in Europe. 
 The Regulatory Price shall not, under any circumstances, be lower than the lowest
prevailing Product price in the European Union (the “Minimum Regulatory Price”). 
 Net Regulatory Price = Regulatory
Price – [Discount + sales taxes (including VAT)]. 
 Discount = any discounts granted by TEVA, provided that 

 

	 	•	 	TEVA provides ERYTECH with details of the discounts granted including the provision of receipt or others documentation; and 

  

	 	•	 	The total Discount does not exceed [***]% of the Minimum Regulatory Price. 

 TEVA acknowledges
that if the real and effective Marketing and Promotional expenses and/or if the real and effective sales are significantly lower than those planned in the Forecasts and GRASPA® Business Model
as specified in Schedule D, the commercial terms shall be reviewed by both Parties in good faith. 
  

	9.2	Invoicing of the Products and Payment: 

 ERYTECH shall invoice for Products after
delivery to TEVA of the Products according to the Transfer Price and for the reimbursement of the Transportation Costs as specified in Article 5.4 (Transportation). TEVA shall pay for the Products, within [***] days after the last day of the month
in which the invoice was issued by ERYTECH, by letter of credit issued by a bank of the Territory and confirmed by a first class bank in favor of ERYTECH. Products shall be paid in Euros. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 ARTICLE 10 - DELIVERY AND RISK OF LOSS 

 

	10.1	Delivery: 

 Unless otherwise agreed upon, ERYTECH shall deliver or arrange for the
delivery of Products at [***] (Address of the Customer) in accordance with conditions of the INCOTERM issued by the International Chamber of Commerce, 2000. 
  

	10.2	Transfer of Title and Transfer of Risk: 

 Title to Products sold pursuant hereto
shall pass to TEVA upon delivery in accordance with Article 10.1. (Delivery) above. In such case, risks shall be transferred to TEVA according to the [***] (Address of the Customer). 

ARTICLE 11 - INTELLECTUAL PROPERTY 
  

	11.1	License. 

 ERYTECH hereby grants to TEVA an exclusive, royalty-free,
non-transferable, non-sublicensable license during the Term of this Agreement to use the ERYTECH Backgrounds Rights and ERYTECH Improvements solely as necessary to perform the Regulatory and Distribution activities in the Territory under this
Agreement. 
  

	11.2	Title. 

  

	 	11.2.a	Ownership right acknowledgment: TEVA acknowledges that ERYTECH has represented to it that ERYTECH is the exclusive owner of any rights to ERYTECH Backgrounds Rights and agrees that ERYTECH can make no warranty as to
ERYTECH Backgrounds Rights other than as to their material existence. 

  

	 	11.2.b	Backgrounds Rights. ERYTECH shall retain all right, title and interest in and to all of the ERYTECH Backgrounds Rights. TEVA agrees that, except as set forth in Article 11.1 (License), it will not have any right, title
or interest in or to the ERYTECH Backgrounds Rights. 

  

	 	11.2.c	 Third Party Claims. ERYTECH represents that no party has asserted a claim, or to ERYTECH’s knowledge
threatened to assert a claim against ERYTECH alleging that the 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	 	
exploitation by ERYTECH and/or TEVA of any of the Backgrounds Rights and the Licensed Trademarks infringes any intellectual property rights of any person or party, and ERYTECH is unaware of any
basis for any Claim alleging such infringement. 

  

	 	11.2.d	TEVA Assistance: TEVA agrees to reasonably assist and execute from time to time documents as ERYTECH may reasonably require and after receiving TEVA’s prior written approval, for the registration,
maintenance, defense of ERYTECH Backgrounds Rights in the Territory, at ERYTECH’s cost and expense. 

 TEVA agrees to
report to ERYTECH, as soon as reasonably possible, any significant information, which may come to its attention with respect to ERYTECH Backgrounds Rights, including potential infringement of or challenge to the validity or ownership of ERYTECH
Backgrounds Rights by a Third-Party. 
  

	 	11.2.e	Legal actions by Third Parties: Any intellectual property proceedings against TEVA/ERYTECH in or outside of the Territory deemed to be infringing any third party rights, including but not exclusively opposition,
nullity, cancellation actions, will be taken solely by ERYTECH and ERYTECH will appoint a counsel of its choice. Costs, damages and interests shall be for the sole account and benefit of ERYTECH. 

ARTICLE 12 - TRADEMARKS. 
  

	12.1	Grant of Rights: 

  

	 	•	 	ERYTECH hereby authorizes TEVA to use ERYTECH Trademarks, free of charge, only to perform the Regulatory and Distribution activities under this Agreement, from the Effective Date to the termination of the Agreement.

  

	 	•	 	TEVA undertakes not to use or promote the ERYTECH Trademarks otherwise than in connection with the sale of the Products. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	12.2	ERYTECH obligations: 

 ERYTECH shall be the sole responsible for, and shall initiate and
control, the preparation, filing, prosecution, grant, maintenance, renewal of ERYTECH Trademarks in the Territory at ERYTECH’s expense. 
  

	 	12.2.a	Legal actions against Third Parties: Any decision relating to bringing trademark proceedings against Third Parties in or outside of the Territory deemed to be infringing ERYTECH Trademarks, including but not exclusively
opposition, nullity, cancellation actions, will be taken solely by ERYTECH and ERYTECH will appoint a counsel of its choice. Costs, damages and interests shall be for the sole account and benefit of ERYTECH. 

 

	 	12.2.b	Loss of Rights: if ERYTECH has lost its rights on ERYTECH Trademarks, ERYTECH shall promptly inform TEVA in writing. TEVA shall immediately cease marketing the Products under the ERYTECH Trademark, except if ERYTECH and
TEVA mutually agree in writing to the contrary. 

  

	 	12.2.c	In this case, ERYTECH shall be the sole to decide, select, protect and own property rights on back-up names which will be necessary to create and use instead of the original ERYTECH Trademark. 

 

	12.3	TEVA Obligations: 

  

	 	12.3.a	Ownership right acknowledgment: TEVA acknowledges that ERYTECH has represented to it that ERYTECH is the exclusive owner of any rights to ERYTECH Trademarks and agrees that ERYTECH can make no warranty as to ERYTECH
Trademarks other than as to their material existence and renounces to any indemnity, compensation in case of loss of rights by ERYTECH or infringement or any other legal actions filed by Third Parties against ERYTECH Trademarks in connection with
their use in the Territory. 

 Moreover, TEVA shall not use, apply for and register the ERYTECH Trademarks as part of its
corporate name, trade name, trading style or other means of corporate or business identification including use and registration of domain names and other Internet key words. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	 	12.3.b	Design of ERYTECH Trademarks: TEVA shall respect the visual style guidelines communicated by ERYTECH to TEVA in writing in order to use the ERYTECH Trademarks. 

TEVA agrees that ERYTECH shall have the right to conduct at any time any usual quality control of the use of the ERYTECH Trademarks. 

 

	 	12.3.c	TEVA Assistance: TEVA agrees to reasonably assist and execute from time to time documents as ERYTECH may reasonably require and after receiving TEVA’s prior written approval, for the registration, maintenance,
defense of ERYTECH Trademarks in the Territory, at ERYTECH’s cost and expense. 

 TEVA agrees to report to ERYTECH, as
soon as reasonably possible, any information, which may come to its attention with respect to ERYTECH Trademarks, including potential infringement of or challenge to the validity or ownership of ERYTECH Trademarks by a Third-Party. 

 

	12.4	Termination of Agreement: 

 Forthwith upon termination of this Agreement, TEVA shall cease to use
the ERYTECH Trademarks. In accordance with Article 17.4 (Consequences of the termination of the Agreement), TEVA shall immediately stop to use ERYTECH Trademarks on promotional materials for selling the Products except in case of remaining stocks,
if any. 
 ARTICLE 13 RECALL 
  

	13.1	Recall due to ERYTECH: If a recall of the Product is required due to a defect in the manufacture, packaging, labeling and transportation to TEVA of the Products and/or any matter whatsoever occurring prior to the
transfer of risk in the Products to TEVA, TEVA shall immediately notify ERYTECH and review with ERYTECH the proposed manner in which the recall is to be carried out. The recall shall be carried out by TEVA wholly at the cost of ERYTECH in as
expeditious manner as possible and in such a way as to comply with good public health practices and to attempt to cause the least disruption of sales of the Products in the Territory and to preserve the goodwill and reputation of the Products and
reputation of TEVA and ERYTECH. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	13.2	Recall due to TEVA: If a recall of the Product is required, due to a defect in the Products occurring after transfer of risk in the Products to TEVA, TEVA shall immediately notify ERYTECH of such event and of the
proposed manner in which such recall is to be carried out. The recall shall be carried out by TEVA, wholly at the cost of TEVA, in as expeditious a manner as possible and in such a way as to comply with good public health practices and to attempt to
cause the least disruption of sales of the Products in the Territory and to preserve the goodwill and reputation of the Products and the goodwill and reputation of TEVA and ERYTECH. 

 

	13.3	ERYTECH shall as soon as reasonably possible inform TEVA in writing in the event of a recall of the Product in any territory in which the Product is being distributed and the reasons for such a recall.

 ARTICLE 14 - STEERING COMMITTEE 
  

	14.1	Composition of the Steering Committee: 

 From the Date of Registration, each Party shall appoint two
(2) Representatives to participate on a steering committee (the “Steering Committee”) to oversee the activities under this Agreement. The Steering Committee shall meet via teleconference at least once a quarter during the Term
of this Agreement and no later than (1) one month after a Party asks for a meeting of the Steering Committee. ERYTECH shall appoint the chairman of the Steering Committee. A precise agenda shall be drawn up before each meeting of the Steering
Committee by the chairman, consulting the Representatives of the other party. Subsequent to each meeting, the chairman shall draw up the minutes and distribute such minutes for signature by both Parties. All decisions of the Steering Committee shall
be made by consensus, with each Party’s representatives on the Steering Committee collectively having one (1) vote. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	14.2	Role: 

 The specific role of the Steering Committee is to review and discuss the parties’ on going
activities, marketing plans, development of the Product, etc. If required, the parties shall also discuss any modifications needed to be made in order to adjust to different situations. 

 

	14.3	Responsibilities: 

 The Steering Committee shall be responsible for coordinating and monitoring the
activities under this Agreement and addressing any disputes that may arise between the Parties in connection therewith. In the event that the Steering Committee is unable to resolve any dispute, either Party may, by written notice to the other, have
such dispute referred to the Senior Management of the Parties, or their respective Representatives, for attempted resolution by good faith negotiations within [***] days after such notice is received. If the Senior Management does not fully settle
such dispute in such [***] day period, and a Party wishes to pursue such dispute further, each such dispute shall be finally resolved in accordance with the provisions set forth in Article 18 (Applicable Law and Dispute). Notwithstanding the
foregoing, it is understood by the Parties that any resolution to any dispute that changes the nature of the Agreement between the parties shall be the subject to a written resolution signed by both Parties and that any temporary solution or
“work around” agreed to by the parties that is inconsistent with the terms of this Agreement shall not operate as a waiver of such term in the future unless such term is intended to do so and such intention is manifested in writing signed
by the Parties. 
  

	14.4	Representatives: 

 At the time of execution of this Agreement, ERYTECH’s Representatives in the
Steering Committee shall be [***] and [***] and those of TEVA shall be [***] and [***]. Each Party may, from time to time, replace its representative by written notice to the other Party specifying the prior representative and the replacement. The
Parties shall, from time to time and if required, include attorneys in Steering Committee meetings for the purpose of assisting in facilitating the discussion of legal matters in such meetings. It is understood that despite the presence of
attorneys, the terms of this Agreement shall control the relationship between the parties and that any waiver or “work around” to any term of this Agreement employed to resolve and issue 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 
arising at Steering Committee or at any other point shall not act as a waiver of the right to enforce such term in the future. Any permanent, binding alteration to this Agreement shall be in
writing and signed by both Parties. 
 ARTICLE 15 - WARRANT - LIABILITY — INDEMNIFICATION - INSURANCE. 

 

	15.1	Warranty by ERYTECH: 

 Except as expressly provided herein, ERYTECH makes no warranty of
any kind, express or implied, of merchantability or fitness for any particular purpose of the Products. 
 ERYTECH warrants that any Product
is of good and merchantable quality and meets the specifications of the Products Approval(s), including packing and labeling specifications. In no event shall ERYTECH be liable for any indirect or consequential loss incurred by TEVA or any other
person howsoever caused. 
  

	15.2	TEVA’s claim: 

 If TEVA claims that a Product did not meet the specifications of the
Products Approval(s), or was not of good and merchantable quality (as set forth in this Agreement), ERYTECH shall conduct investigations on the concerned shipment or batch. If ERYTECH agrees with TEVA’s claim, ERYTECH at TEVA’s option
shall either replace such shipment of Product as soon as reasonably possible, at no cost to TEVA or give credit for payment made by TEVA for such shipment including any related reasonable expenses to TEVA. If the Parties are unable to resolve their
differences with respect to whether the Products meet the agreed specifications, then either Party may refer the matter to the Steering Committee in accordance with Article 14 (Steering Committee). In the event that the Steering Committee can not
reach an amicable solution, the Steering Committee may choose to approach an independent laboratory, in order to resolve the matter. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	15.3	Warranty by TEVA: 

 Subject to section 15.1 above, ERYTECH shall not be responsible for
any damages or losses resulting from the purchase, distribution, promotion, use or sale of Products by TEVA after the transfer of risk in Products to TEVA. 
  

	15.4	Indemnification by TEVA: 

 Subject to Article 15.6 (No consequential damages), TEVA shall
indemnify ERYTECH, its servants, agents and contractors in respect of all damages incurred by ERYTECH by reason of or arising out of any actions, suits, claims, demands, costs, charges and expenses (including but not limited to reasonable
attorneys’ fees) for losses to the extent that such losses shall have been occasioned by any damage to the Product caused by TEVA, its servants or agents after transfer of risk in the Product to TEVA, or by a negligence of TEVA, its servants
and agents, however, this indemnity shall not apply where and to the extent that damages shall have been caused solely by a breach by ERYTECH of the provisions of the Agreement. 

 

	15.5	Indemnification by ERYTECH: 

 Subject to Article 15.6 (No consequential damages), ERYTECH
shall indemnify TEVA, its servants, agents and contractors in respect of all damages incurred by TEVA by reason of or arising out of any actions, suits, claims, demands, costs, charges and expenses (including but not limited to reasonable
attorneys’ fees) for losses to the extent that such losses shall have been occasioned by: (i) the Product, its use and/or any of its side effects (ii) any deviation from the Product’s specifications, (iii) non-compliance
with any law and/or regulation in the Territory, and/or (iv) by a negligence of ERYTECH, its servants and agents, however, this indemnity shall not apply where and to the extent that damages shall have been caused solely by a breach by TEVA of
the provisions of the Agreement. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	15.6	No consequential damages: 

 Subject to all provisions of this Agreement, each Party (in this Article
referred to as “such Party”) excludes all liability for consequential loss suffered by the other Party as a result of any breach of this Agreement by such Party except as regards any liability resulting from the gross negligence, willful
misconduct, reckless or fraud of such Party. 
  

	15.7	Insurance: 

  

	 	15.7.1	In order to ensure the fulfillment of ERYTECH’s responsibilities, obligations and liability pursuant to any law and/or this Agreement, ERYTECH undertakes to take out and maintain, at its expense sufficient
insurance. The insurance described in this section shall include, at the least, as follows: 

 Product Liability
Insurance: with a limit of [***] Euros ([***]) per occurrence and in a yearly aggregate in respect of any injury or damage which might be caused in consequence of any defect in the Product for any demand claim or claims caused by or arising out
of or related to the Product, its quality, usage, designation, its usage instruction and damage to the Product by ERYTECH. 
 Upon
commencing to sell and distribute the Product anywhere in the world, the limit of the Policy, as described above, would be increased by ERYTECH, to an amount that would cover the potential risks and exposure of this Agreement. 

 

	 	15.7.2	In order to ensure the fulfillment of TEVA’s responsibilities, obligations and liability pursuant to any law and/or this Agreement, TEVA undertakes to take out and maintain, at its expense a sufficient insurance in
excess of self insured retention. The insurance described in this section shall include, at the least, as follows: 

Product Liability Insurance: with a limit of Euros [***] ([***] Euros) per occurrence and in the yearly aggregate, in respect of any
injury or damage which might be caused in consequence of any defect in the Product for any demand claim or claims caused by or arising out of or related to the Product, its quality, usage, designation, its usage instruction and damage to the Product
by TEVA. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	 	15.7.3	All the above mentioned Insurance shall be referred hereinafter as the “Policies”. 

The Policies shall apply retroactively from the earlier of the two following dates: 

 

	 	•	 	the Date of Launch 

  

	 	•	 	the date the Product is authorized to be sold in compassionate use. 

  

	 	15.7.4	With respect of Professional Liability Insurance and Product Liability Insurance Policies, each Party undertakes to hold and maintain its Policies in force through any period that such party might be liable and
responsible by law, but not less than minimum period of [***] years from the last supply date. 

  

	 	15.7.5	The Policies required under this Article shall be obtained from an insurance carrier with an A.M. Best rating or any other similar rating agency of at least A. 

 

	 	15.7.6	The Parties are solely responsible for the payment of any premium or self insured retention/deductibles or any other payments related to their insurances. 

 

	 	15.7.7	ERYTECH’s Policies will be extended to include TEVA as an additional named insured for any act or omission of ERYTECH and shall be valid, at least in the Territory, and in every country in which the Product is
manufactured, handled and/or transported. 

 TEVA’s Policies will be extended to include ERYTECH as an additional named
insured for any act or omission of TEVA and shall be valid, at least in the Territory, and in every country in which the Product is manufactured, handled and/or transported. 

ERYTECH’s Policies shall be primary, preliminary and non-contributory to any of TEVA’s policies, for any act or omission of ERYTECH
only. 
  

	 	15.7.8	The Parties undertake that the Policies will neither be cancelled nor materially amended during the period of the insurance, unless at least [***] days prior written notice thereof is sent by registered mail to the
other Party. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	 	15.7.9	If a Party shall not provide an insurance certificate to the other Party, the other Party shall be entitled; without reducing any of the other Party’s other rights, as per the Agreement and in accordance with any
law, to obtain the insurance on its own and to charge the Party with all expenses involved. 

  

	 	15.7.10	In case of a claim and/or a demand and/or knowledge related to erosion and/or exhaustion of limits of liability of any of Party’s insurance required under the Agreement (hereinafter: “the Limits of
Liability”) due to and/or a result from any event (whether paid or unpaid) each Party undertakes to purchase (promptly after the claim and/or a demand and/or knowledge related to erosion and/or exhaustion as detailed above, the earlier)
insurance to reinstate the Limits of Liability as detailed in the Agreement. 

  

	 	15.7.11	Nothing in this clause (15.7 insurance) will reduce a Party’s obligations, in accordance with this Agreement and in accordance with any law. 

 

	 	15.7.12	The Parties’ obligations pursuant to this clause, including all the sub-clauses hereof, constitute a fundamental condition of the Agreement and a breach of any of them shall be deemed a fundamental breach of the
Agreement. 

  

	 	15.7.13	Each Party will provide the other with a certificate of insurance evidencing the coverage set forth in this Article and thereafter shall provide the other Party such a certificate of insurance upon request.

 ARTICLE 16 - SECRECY, NON-USE AND PRESS RELEASE. 

 

	16.1	Nondisclosure: 

 All information which is received, during the term of this Agreement, by either Party
(the “Recipient”) from the other Party (the “Disclosing Party”) shall be maintained in confidence and shall not be disclosed to any Third-Party or used for any purposes other than set out herein, without the prior
consent of the Disclosing Party, except to the extent that such information: 
  

	 	•	 	is known to the Recipient prior to its disclosure by the Disclosing Party, provided that the Recipient is able to provide written evidence of such prior knowledge; or 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	 	•	 	is obtained by the Recipient from a source other than the Disclosing Party which source: 

  

	 	•	 	did not require the Recipient to hold such information in confidence; 

  

	 	•	 	did not limit or restrict the Recipient’s use thereof; or 

  

	 	•	 	has become public knowledge otherwise than through the fault of the Recipient; or 

  

	 	•	 	has been developed by the Recipient independently of the information received from the Disclosing Party as shown by the Recipient’s written records. 

 

	16.2	No Implied Rights: 

 It is agreed that except to the extent expressly provided otherwise herein
disclosure of information hereunder shall not constitute any grant, option or license under any patent, technology or others rights in or to such information. 
  

	16.3	Confidentiality of the Agreement. 

 Except as provided in Article 16.5 (Press Release) each Party shall
maintain the confidentiality of this Agreement and all provisions of this Agreement and, without the prior consent of the other Party, neither Party shall make any press release or other public announcement or otherwise disclose this Agreement or
any of its provisions to any Third Party (a) other than its Representatives provided that such persons are bound to maintain the confidentiality of the Agreement and (b) except for such disclosures as may be required by applicable law or
by regulation, in which case the Disclosing Party shall provide the other Party with prompt advance notice of such disclosure so that the other party has the opportunity if it so desires to seek a protective order or other appropriate remedy. 

 

	16.4	Communication with Representatives. The Parties shall: 

  

	 	•	 	Ensure that only its Representatives, who have a “need to know” such Confidential Information for purposes of this Agreement, shall have access hereto; 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	 	•	 	Ensure that, prior to disclosure of Confidential Information, each Representatives agrees to be subject to confidentiality obligations no less onerous than those contained in this Agreement. 

 

	16.5	Press release 

 Upon the signature of this Agreement, ERYTECH is entitled to publish a press release as
agreed in Schedule B which will be published on a time and date agreed upon by the Parties, but no later than two (2) weeks after the Effective Date. 

ARTICLE 17 - TERM AND TERMINATION. 
  

	17.1	Term and renewal: 

 This Agreement shall take effect as of the Effective Date and shall continue in
effect for a ten year period after the Date of Launch (the “Term”), unless terminated earlier as set forth herein. Thereafter, the Agreement shall automatically be renewed for successive periods of five (5) years unless one of
the Parties decide not to renew it informing the other Party of its decision by registered letter with acknowledgement of receipt at least six (6) months before the date of anniversary of the Effective Date. 

 

	17.2	Termination for cause: 

 This Agreement may be terminated at any time forthwith by notice by either Party
(the “Electing Party”) to the other if the other Party fails to observe, perform or otherwise breaches any of its material covenants, agreements or obligations under this Agreement in any material respect, provided such failure
continues for a period of [***] days after receipt by the other Party of notice thereof from the Electing Party specifying such failure to cure the same. 
  

	17.3	Termination by ERYTECH: 

 ERYTECH shall have the right to terminate the Agreement if TEVA
fails to reach the Minimum Regulatory Price, in accordance with Article 9 (Transfer Price and Payment). ERYTECH shall not pay TEVA any indemnity or reimbursement whatsoever for terminating of this Agreement in accordance with this Article. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	17.4	Termination by TEVA: 

 TEVA shall have the right to terminate this Agreement by providing
ERYTECH [***] days prior written notice in the event that ERYTECH ceases to provide TEVA with Products ordered for duration of [***] consecutive months, if TEVA provided ERYTECH with prior written notice and ERYTECH failed to cure the breach;
ERYTECH shall [***]. 
 For the avoidance of any doubt, ERYTECH shall not be responsible or liable for any failure of supply if such failure
results from events or circumstances reasonably beyond the control of ERYTECH (or any of its Representatives) and which, despite the exercise of reasonable diligence, ERYTECH is unable to prevent, avoid or remove. 

 

	17.5	Termination due to intellectual property reasons. 

 In the event that TEVA is negatively
affected in or is unable to, temporarily, indefinitely or permanently, register, launch, market and/or continue to distribute and/or market the Product due to intellectual property reasons, including without limitations, due to infringement of third
party’s rights, TEVA shall have the right to terminate the Agreement upon [***] days written notice and without compensation. 
  

	17.6	Consequences of the termination or expiration of this Agreement: 

  

	17.6.1	Termination or expiration of this Agreement for any reason whatsoever shall not affect any Party’s obligations to pay any amount accruing to ERYTECH or TEVA respectively, under the provisions of this Agreement
while it was in effect and shall not relieve either Party of any liability having accrued hereunder prior to the effective date of such expiration or termination. 

 

	17.6.2	In addition, anything herein to the contrary notwithstanding, the following provisions of this Agreement shall survive termination or expiration of this Agreement: Articles 4 (Adverse Events Reporting), 11 (Intellectual
Property), 12 (Trademarks), 13 (Recall), 15 (Warranty-Liability-Indemnification), 16 (Secrecy, Non use and Press release), this Article 17.4 (Consequences of the termination or expiration) and 18 (Applicable Law and Disputes) 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	17.6.3	Upon termination or expiration of this Agreement for any reason whatsoever, the Parties shall immediately return to the other all confidential information in documentary or printed form and any copies thereof and shall
thereafter cease to use such information but without prejudice to the then surviving confidentiality obligations provided for in Article 16 (Secrecy and Non-use), except for one (1) copy of all confidential information, to be kept for archival
purposes. 

  

	17.6.4	Upon termination or expiration of this Agreement for any reason whatsoever, TEVA shall take all necessary measures to the effect that any Product Approval held by TEVA on behalf of ERYTECH be transferred under
ERYTECH name (or under the name of a ERYTECHts Affiliate designated by ERYTECH) as promptly as reasonably possible as set forth in Article 3.3 (Regulatory). 

  

	17.6.5	Upon termination or expiration of this Agreement for any reason whatsoever, TEVA shall comply with its obligations with respect to its use of ERYTECH Trademarks as set forth in Article 12 (Trademarks).

 ARTICLE 18 - APPLICABLE LAW AND DISPUTES. 

 

	18.1	This Agreement shall be governed and construed in accordance with the laws of [***]. 

  

	18.2	Any and all disputes which cannot reach an amicable settlement, arising from or in connection with the present Agreement, shall be settled by binding arbitration in accordance with the Rules of Conciliation and
Arbitration of the International Chamber of Commerce (“ICC”) in effect at the time the demand for arbitration is filed by the demanding party with the ICC, as supplemented by the further requirements of this Article.

  

	18.3	 Such arbitration shall be conducted by one (1) arbitrator, selected by both parties. If the Parties fail to
agree on an arbitrator, such arbitrator shall be appointed by the ICC promptly thereafter. The place of Arbitration shall be [***] in the English language and the award shall be rendered in [***]. The decision of the arbitrator shall be final and
conclusive and shall be 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	 	
binding upon the Parties. By agreeing to arbitration, the Parties do not intend to deprive any court of its jurisdiction to issue a pre-arbitral injunction, pre-arbitral attachment, or other
order in aid of arbitration proceedings and the enforcement of any award. 

 ARTICLE 19 - FORCE MAJEURE. 

 

	19.1	No Party hereto shall be responsible or liable to the other Party hereto for any failure to perform any of its agreements, covenants or obligations under this Agreement if such failure results from events or
circumstances reasonably beyond the control of such Party (or any of its Representatives) and which, despite the exercise of reasonable diligence, such Party is unable to prevent, avoid or remove (“Events of Force Majeure”).

  

	19.2	The affected Party shall exert all reasonable efforts to eliminate, cure or overcome any such Event of Force Majeure and to resume performance hereunder with all possible speed. Notwithstanding the foregoing, to
the extent that an Event of Force Majeure continues for a period in excess of six (6) months, the Parties agree to negotiate in good faith either (i) to resolve the Event of Force Majeure, if possible, (ii) to extend their mutual
agreement the time period to resolve, eliminate or overcome such Event or (iii) to terminate this Agreement. 

ARTICLE 20 - MISCELLANEOUS. 
  

	20.1	Amendment: This Agreement shall be modified only by endorsement signed by Representatives of the Parties. 

  

	20.2	No assignment: Either Party may not assign this Agreement. 

 Notwithstanding the
foregoing, each Party may assign this Agreement to any of its Affiliates provided that such Affiliates agree to be bound by all the provisions of the Agreement. 
  

	20.3	Successors and assigns. This Agreement shall inure to the benefit of and be binding upon the Parties hereto and their respective successors and permitted assigns. 

 

	20.4	[***] 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

	20.5	Entire agreement. This Agreement constitutes the entire Agreement between the Parties in respect of the subject matter hereof. This Agreement supersedes any and all pre-existing agreements, either oral or
in writing. There are not and shall not be any oral statements, representations, warranties, undertakings or agreements between the Parties in respect of the subject matter hereof other than as provided by this Agreement and any mutually accepted
written amendments hereto. 

  

	20.6	Superiority: No provision on TEVA purchase order form or on ERYTECH’s general conditions of sale which may purport to impose different conditions under TEVA or ERYTECH shall modify the terms and
conditions of this Agreement. 

  

	20.7	No waiver. The failure on the part of either Party hereto to exercise or enforce any right conferred upon it by this Agreement shall not be a waiver of any such right nor shall any single or partial
exercise of any right or power hereunder or further exercise thereof operate so as to bar the later exercise or enforcement thereof. 

  

	20.8	No power of representation: Except as expressly provided in this Agreement, TEVA shall not incur any liability on behalf of ERYTECH or in any way pledge or purport to pledge ERYTECH’s credit or accept
any order or make any contract binding upon ERYTECH. 

  

	20.9	Independent Contractors. The relationship between TEVA and ERYTECH shall be that of an independent contractor. No Party shall have the right, title or authority to enter into any contract, agreement or
commitment on behalf of the other or to bind the other Party in any manner whatsoever. 

  

	20.10	Severability. If any provision of this Agreement is held invalid or unenforceable, such invalidity or unenforceability shall not affect other provisions of this Agreement which can be given effect without
the provision(s) held invalid or unenforceable, and to this end, the provisions of this Agreement shall be deemed severable. 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 IN WITNESS WHEREOF, the Parties hereto, through their authorized Representatives, have set their hands
as of the date first above written, whereby they evidence their intent to be legally bound. 
  

	
	ERYtech Pharma SA.
	
	 /s/ Pierre-Oliver GOINEAU

	Mr. Pierre-Olivier GOINEAU
	Chief Executive Officer
	
	Teva Pharmaceutical Industries Limited
	
	 /s/ Ron Mayron

	Ron Mayron
	Managing Director – Teva Israel, Vice President I.C.A.
	
	 /s/ Dan Danieli

	Dan Danieli
	Managing Director – Pharma, Teva Israel
	
	 /s/ Efrat Klachevsky

	Efrat Klachevsky
	Director, Business Development, Teva Israel

  
 

 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 SCHEDULE A: 

UPFRONTS AND MILESTONES 
 Up front
Payment: As a consideration for the license to distribute the Product in the Territory, TEVA shall pay to ERYTECH within [***] days after the last day of the month in which the invoice was issued, a fee of 40 000 Euros. 

Milestone Payments (within [***] days after the last day of the month in which the invoice was issued the invoice regarding the milestone was issued):

  

	 	•	 	Upon [***]: a fee of [***] Euros. 

  

	 	•	 	Upon [***]: a fee of [***] Euros. 

  

	 	•	 	Upon [***]: a fee amounting to [***]% of the [***] (as defined below). 

 [***] 

TEVA Operating Profit or TEVA OP = Transfer Price (as defined in Article 9 (Transfer Price)) - (TEVA Transportation Costs + TEVA Marketing (including
Regulatory expenses) and Promotional Expenses + TEVA General & Administrative expenses) 
 TEVA Transportation Costs = [***]% Transportation
Costs + any amount exceeding [***] € per Product (to be reimbursed to ERYTECH) 
 TEVA General & Administrative expenses or TEVA G&A:

  

	 	•	 	From the first year to the [***] (included) = [***] % of Total Sales 

  

	 	•	 	From the [***] year = [***]% Total Sales 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 SCHEDULE B: 
  

 
 Press Release 

••••••••• 

ERYtech Pharma to partner with Teva 

for long term distribution agreement in Israel 

Lyon (France), Philadelphia (USA), January xxth 2011 

ERYtech Pharma is pleased to announce it has signed an exclusive long term agreement with Teva for the registration, marketing, distribution and sale of
Graspa®, the company’s lead product, in Israel. 
 ERYtech is a leading specialty pharma
company developing new high value medicinal products for unmet clinical needs in the field of oncology, heamatology and immunology. Graspa® is the company’s lead product currently in
pivotal trial in Europe. Teva leading position, long history in oncology and specialty segment will provide a solid platform for Graspa® and made them an ideal partner for product market
introduction in Israel. ERYtech anticipates that first sales could be generated in less than 15 months. 
 Under the terms of the agreement, Teva will
submit the drug for approval in Israel, market and distribute it in the territory for a long term period. Teva will pay milestone payments in addition to sharing profit on the basis of purchase price agreed with Teva. 

“This collaboration represents a significant milestone as first distribution agreement and a major step in the worldwide product expansion” said
Pierre-Olivier Goineau, Chief Executive Officer. “Thanks to its good efficacy and safety profile, Graspa®, will bring major therapeutic value for Israeli patients in ALL.” 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 About Graspa 

GRASPA® is a new enzyme formulation of L-asparaginase with a safer and broader range of clinical uses
compared to existing forms due to the enzymes entrapment and protection inside the homologous red blood cell. GRASPA®’s (encapsulating L-asparaginase in red blood cells) interest is to
overcome all existing limitations associated with conventional L-asparaginase through a longer efficacy, better compliance, reduced dosage and an increased safety profile. 

About ERYtech Pharma 
 ERYtech Pharma (Lyon,
Philadelphia) is a specialty pharma company developing innovative therapeutic solutions based on its proprietary technology and expertise in the physiological properties of erythrocytes. The company addresses serious pathologies, orphan indications
or sub-populations of patients, particularly in the fields of haematology, cancer and metabolic diseases. It has built in less than six years a strong pipeline with very ambitious programs and a powerful proprietary R&D platform offering large
possibilities of new therapeutics products and applications. 
 Contact Press; 

ERYtech Pharma - 60, Avenue Rockefeller - Batiment Adenine - 69008 - LYON - France 

ERYtech Pharma - US Office - 3711 Market Street, 19104 Philadelphia PA - USA 

contact@erytech.com_www.erytech.com 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 SCHEDULE C: 

[***] 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 ***Text Omitted and Filed Separately 

Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 230.406 
  

 SCHEDULE D: 

[***] 

  
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]